A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
Status:
Withdrawn
Trial end date:
2017-07-19
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the
single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years
of age) diagnosed with moderate-to-severe Primary Restless Legs Syndrome (RLS).